Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for being primarily excreted via the hepatobiliary system rather than renally. ## Primary Indications Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control. ## Adult Dosing 5 mg orally once daily. May be taken with or without food. ## Pediatric Dosing Safety and efficacy have not been established in patients younger than 18 years. Use is generally not recommended in pediatric populations. ## Dose Adjustments * **Renal Impairment:** No dose adjustment necessary regardless of creatinine clearance. * **Hepatic Impairment:** No dose adjustment necessary. ## Contraindications * History of serious hypersensitivity reactions to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). ## Adverse Effects * **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues). * **Serious:** Acute pancreatitis, severe/disabling arthralgia, bullous pemphigoid, hypersensitivity reactions. ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy. If combined, monitor glycemic control closely. * **Insulin/Insulin Secretagogues (e.g., sulfonylureas):** Increased risk of hypoglycemia; a lower dose of the secretagogue may be clinically appropriate. ## Monitoring * **HbA1c:** Generally every 3–6 months. * **Blood Glucose:** For patient self-monitoring or if symptomatic for hypoglycemia. * **Clinical Signs:** Monitor for signs of pancreatitis (persistent, severe abdominal pain) and hypersensitivity reactions. ## Clinical Pearls * **Renal Sparing:** Unlike other DPP-4 inhibitors (sitagliptin, saxagliptin), linagliptin does not require dose adjustment for renal impairment, making it a favorable choice in patients with chronic kidney disease. * **Weight Neutral:** Linagliptin is typically weight-neutral and has a low risk of monotherapy-induced hypoglycemia. * **Pancreatitis:** Discontinue immediately if pancreatitis is suspected. * **Arthralgia:** Severe joint pain can occur at any time after starting therapy; consider discontinuation if pain develops. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug information can change. Always verify the most current prescribing information via the manufacturer’s package insert, institutional pharmacy protocols, or clinical decision support software before prescribing or administering medication.